Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.

Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, Walter M, Burns CJ, Treutlein H, Wilks AF, Rossjohn J.

Blood. 2006 Jan 1;107(1):176-83. Epub 2005 Sep 20.

PMID:
16174768
[PubMed - indexed for MEDLINE]
Free Article
2.

Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.

Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, Fantino E, Rossjohn J, Lucet IS.

J Mol Biol. 2009 Mar 20;387(1):219-32. doi: 10.1016/j.jmb.2009.01.041. Epub 2009 Jan 29.

PMID:
19361440
[PubMed - indexed for MEDLINE]
3.

Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain.

Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A.

Genes Cells. 1999 Jun;4(6):339-51.

PMID:
10421843
[PubMed - indexed for MEDLINE]
4.

Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.

Chrencik JE, Patny A, Leung IK, Korniski B, Emmons TL, Hall T, Weinberg RA, Gormley JA, Williams JM, Day JE, Hirsch JL, Kiefer JR, Leone JW, Fischer HD, Sommers CD, Huang HC, Jacobsen EJ, Tenbrink RE, Tomasselli AG, Benson TE.

J Mol Biol. 2010 Jul 16;400(3):413-33. doi: 10.1016/j.jmb.2010.05.020. Epub 2010 May 15.

PMID:
20478313
[PubMed - indexed for MEDLINE]
5.

Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.

Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, Uckun FM.

Clin Cancer Res. 1999 Jun;5(6):1569-82.

PMID:
10389946
[PubMed - indexed for MEDLINE]
Free Article
6.

Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function.

Flowers LO, Johnson HM, Mujtaba MG, Ellis MR, Haider SM, Subramaniam PS.

J Immunol. 2004 Jun 15;172(12):7510-8.

PMID:
15187130
[PubMed - indexed for MEDLINE]
Free Article
7.

The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop.

Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A.

EMBO J. 1999 Mar 1;18(5):1309-20.

PMID:
10064597
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.

Saharinen P, Silvennoinen O.

J Biol Chem. 2002 Dec 6;277(49):47954-63. Epub 2002 Sep 25.

PMID:
12351625
[PubMed - indexed for MEDLINE]
Free Article
9.

Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors.

Brown K, Long JM, Vial SC, Dedi N, Dunster NJ, Renwick SB, Tanner AJ, Frantz JD, Fleming MA, Cheetham GM.

J Biol Chem. 2004 Apr 30;279(18):18727-32. Epub 2004 Feb 6.

PMID:
14766749
[PubMed - indexed for MEDLINE]
Free Article
10.
11.

Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation].

Sandberg EM, Ma X, He K, Frank SJ, Ostrov DA, Sayeski PP.

J Med Chem. 2005 Apr 7;48(7):2526-33.

PMID:
15801842
[PubMed - indexed for MEDLINE]
12.

Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases.

Yin T, Shen R, Feng GS, Yang YC.

J Biol Chem. 1997 Jan 10;272(2):1032-7.

PMID:
8995399
[PubMed - indexed for MEDLINE]
Free Article
13.

A novel function for a glucose analog of blood group H antigen as a mediator of leukocyte-endothelial adhesion via intracellular adhesion molecule 1.

Zhu K, Amin MA, Kim MJ, Katschke KJ Jr, Park CC, Koch AE.

J Biol Chem. 2003 Jun 13;278(24):21869-77. Epub 2003 Apr 2.

PMID:
12672794
[PubMed - indexed for MEDLINE]
Free Article
14.

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.

Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, Zhao H, Morgenstern KA.

Structure. 1999 Jun 15;7(6):651-61.

PMID:
10404594
[PubMed - indexed for MEDLINE]
15.

Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1.

Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T.

Mol Cell Biol. 1996 Dec;16(12):6985-92.

PMID:
8943354
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

Saharinen P, Vihinen M, Silvennoinen O.

Mol Biol Cell. 2003 Apr;14(4):1448-59.

PMID:
12686600
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.

Dalgarno D, Stehle T, Narula S, Schelling P, van Schravendijk MR, Adams S, Andrade L, Keats J, Ram M, Jin L, Grossman T, MacNeil I, Metcalf C 3rd, Shakespeare W, Wang Y, Keenan T, Sundaramoorthi R, Bohacek R, Weigele M, Sawyer T.

Chem Biol Drug Des. 2006 Jan;67(1):46-57.

PMID:
16492148
[PubMed - indexed for MEDLINE]
18.

Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.

McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP, Fischer PM.

Chem Biol. 2004 Apr;11(4):525-34.

PMID:
15123247
[PubMed - indexed for MEDLINE]
19.

Determination of the transphosphorylation sites of Jak2 kinase.

Matsuda T, Feng J, Witthuhn BA, Sekine Y, Ihle JN.

Biochem Biophys Res Commun. 2004 Dec 10;325(2):586-94.

PMID:
15530433
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk